Genome-Based Therapeutics: Era of Precision Medicine in Genetic Epilepsies and Epileptic Encephalopathies

Overview

Journal Ann Indian Acad Neurol

Specialty Neurology

Date 2023 Nov 29

PMID 38022486

Authors

Aarthi Balaji

Smilu Mohanlal

Divya Pachat

Sachin Suresh Babu

Ek Suresh Kumar

Najiya Mamukoya

Syama Das

Affiliations

Soon will be listed here.

Abstract

Introduction: The recent evolution of genomics has led to the development of targeted therapeutics, revolutionizing medical approaches. This study aimed to assess the impact of genetic testing on the current epilepsy management paradigm with a specific focus on the variability of outcomes subsequent to genetic diagnoses.

Methodology: Data were collected retrospectively from a cohort of children aged 1-18 years, diagnosed with refractory epilepsy of confirmed genetic origin. The participants received care at a quaternary care center's pediatric neurology clinic from August 2019 to June 2021. The collected information included demographic characteristics, seizure types, EEG findings, imaging abnormalities, genetic diagnoses, attempted treatments, and seizure outcomes.

Results: Among the 210 children with confirmed genetic diagnoses, 74 were included in the study. The gender distribution comprised 45 males and 29 females. Within the cohort, 68/74 exhibited single gene variations, with 23 cases associated with sodium/potassium/calcium channelopathies. Precision medicine could be applied to 25/74 cases. 17/74 children (22.97%) experienced a reduction of up to 50% in seizure frequency due to precision medicine implementation.

Conclusion: While our study indicates the significance of genetic insights in adapting treatment approaches for pediatric epilepsy, it is important to temper our conclusions. The retrospective nature of our study confines our ability to definitively gauge the extent of precision medicine's utility. Our findings suggest the potential of genetic information to enhance epilepsy management, but the true impact of precision medicine can only be established through prospective investigations.

References

French J, Lawson J, Yapici Z, Ikeda H, Polster T, Nabbout R . Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016; 388(10056):2153-2163. DOI: 10.1016/S0140-6736(16)31419-2. View

Symonds J, Zuberi S, Stewart K, McLellan A, ORegan M, MacLeod S . Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. 2019; 142(8):2303-2318. PMC: 6658850. DOI: 10.1093/brain/awz195. View

Kuersten M, Tacke M, Gerstl L, Hoelz H, Stulpnagel C, Borggraefe I . Antiepileptic therapy approaches in KCNQ2 related epilepsy: A systematic review. Eur J Med Genet. 2019; 63(1):103628. DOI: 10.1016/j.ejmg.2019.02.001. View

Moller R, Johannesen K . Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers. Neurotherapeutics. 2015; 13(1):190-1. PMC: 4720666. DOI: 10.1007/s13311-015-0403-5. View

Depienne C, Leguern E . PCDH19-related infantile epileptic encephalopathy: an unusual X-linked inheritance disorder. Hum Mutat. 2012; 33(4):627-34. DOI: 10.1002/humu.22029. View

Heron S, Grinton B, Kivity S, Afawi Z, Zuberi S, Hughes J . PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet. 2012; 90(1):152-60. PMC: 3257886. DOI: 10.1016/j.ajhg.2011.12.003. View

Lotte J, Bast T, Borusiak P, Coppola A, Cross J, Dimova P . Effectiveness of antiepileptic therapy in patients with PCDH19 mutations. Seizure. 2016; 35:106-10. DOI: 10.1016/j.seizure.2016.01.006. View

Mitta N, Menon R, McTague A, Radhakrishnan A, Sundaram S, Cherian A . Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience. Epilepsy Res. 2020; 166:106398. DOI: 10.1016/j.eplepsyres.2020.106398. View

Balestrini S, Chiarello D, Gogou M, Silvennoinen K, Puvirajasinghe C, Jones W . Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies. J Neurol Neurosurg Psychiatry. 2021; 92(10):1044-1052. PMC: 8458055. DOI: 10.1136/jnnp-2020-325932. View

10.

Myers K, Scheffer I . Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies. Annu Rev Pharmacol Toxicol. 2021; 62:641-662. DOI: 10.1146/annurev-pharmtox-052120-084449. View

11.

Fulton S, Van Poppel K, McGregor A, Mudigoudar B, Wheless J . Vagus Nerve Stimulation in Intractable Epilepsy Associated With SCN1A Gene Abnormalities. J Child Neurol. 2017; 32(5):494-498. DOI: 10.1177/0883073816687221. View

12.

Gardella E, Moller R . Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes. Epilepsia. 2020; 60 Suppl 3:S77-S85. DOI: 10.1111/epi.16319. View

13.

Mohanlal S, Bindu P, Sureshbabu S, Kumar S . Variable treatment response in a patient with pyridoxal phosphate oxidase (PNPO) deficiency- understanding the paradox. Epilepsy Behav Rep. 2020; 14:100357. PMC: 7210397. DOI: 10.1016/j.ebr.2020.100357. View

14.

Chen C, Fang F, Wang X, Lv J, Wang X, Jin H . Phenotypic and Genotypic Characteristics of Associated Seizure Diseases. Front Mol Neurosci. 2022; 15:821012. PMC: 9096348. DOI: 10.3389/fnmol.2022.821012. View

15.

Slowinska M, Kotulska K, Szymanska S, Roberds S, Fladrowski C, Jozwiak S . Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries. Pediatr Neurol. 2020; 115:21-27. DOI: 10.1016/j.pediatrneurol.2020.11.003. View